How to Use This Book

This is a long book about a field where most readers arrive with one urgent question. You do not have to read it front to back to get your answer — but you do have to read Chapter 5.

The one non-negotiable chapter

Chapter 5, "How to Evaluate Peptide Evidence," is required reading on every path through this book. It is the only chapter that is.

Every other chapter tells you what is known about some molecule. Chapter 5 teaches you how anyone knows anything at all: what a randomized trial buys you that an observational study cannot, why an animal result is a reason to run a trial rather than a preview of it, how a surrogate endpoint can make a useless drug look excellent, why "a 20% reduction in cardiovascular events" and "1.5 percentage points over three years" describe the identical result, and how one honest trial can report two different weight-loss figures without anyone lying.

Skip it and you have a book of verdicts to memorize. Read it and you have a method — one that will still work on a peptide invented ten years after this book was published.

Five paths through the book

Pick the one that matches why you are here. Every path includes Chapters 1–2 (what peptides are and how they work), Chapters 5–6 (evidence and hype), and Chapter 40 (the capstone).

💊 GLP-1 Focus — "I want to understand Ozempic, Wegovy, and Mounjaro"

Route: 1 → 2 → 4 → 5 → 6 → 7 → 8 → 9 → 10 → 11 → 12 → 13 → 39 → 40 → 41 → 44

The shortest route to genuine competence on the drugs everyone is talking about. Chapter 7 is the biology, Chapter 8 is semaglutide in full, Chapter 9 is tirzepatide and what comes after, Chapter 10 is the expanding list of things these drugs appear to treat, and Chapter 12 is the cost, access, and compounding fight. Chapter 39 turns all of it into a conversation with a clinician. Chapters 41 and 44 close the loop on the part you have actually been living through — how "Ozempic" became a word that no longer means a drug, and what a society on these medicines can and cannot yet claim about itself. Roughly 15 chapters. Start here if a friend or family member just started one of these drugs.

🏋️ Performance Focus — "I'm in the fitness world and I want to know what actually works"

Route: 1 → 2 → 3 → 4 → 5 → 6 → 14 → 15 → 16 → 17 → 18 → 19 → 31 → 34 → 38 → 40 → 42 → 43

This path is built for the reader who has already seen a hundred confident forum posts. Chapters 14 through 19 cover growth hormone, the secretagogues, the muscle peptides, BPC-157, TB-500 and the thymosins, and the gray market itself. Chapter 31 explains where several of these compounds actually came from — veterinary medicine — and why that is a question rather than a credential. Chapter 34 shows how anyone determines what is genuinely in a vial. Chapter 38 covers doping status.

Read Chapters 5 and 6 first, even if you are impatient. Part III is where this book will most often disagree with what you have read elsewhere, and Chapter 5 is the reason it disagrees. Without it, Part III is just another opinion. Chapters 42 and 43 close the path by examining the economics of the people whose posts sent you here, and the argument that enhancement is coming whether anyone plans for it or not.

🔬 Science Focus — full sequential reading

Route: 1 → 44, in order.

The book is built to be read this way. Part I gives you the molecular and evidentiary foundation, Parts II through V apply it across every major peptide class, Part VI explains how these molecules are made, modified, tested, and discovered, Part VII synthesizes everything into a reference you keep, and Part VIII turns the same method on claims about society rather than about molecules. Roughly 65–85 hours with the exercises. This is the path for students, for clinicians, and for anyone who wants the whole field rather than one corner of it.

💄 Cosmetic Focus — "I want to understand what's in my skincare"

Route: 1 → 2 → 4 → 5 → 6 → 30 → 33 → 34 → 37 → 40 → 42

Short and unusually satisfying. Chapter 4 explains why getting a peptide into anything is the central problem of the entire field; Chapter 30 explains why your skin is specifically excellent at keeping molecules out, which reframes the whole product category. Chapter 33 covers the engineering that cosmetic peptides are named after. Roughly 8 chapters, and you will never read an ingredient list the same way.

🏥 Clinical Focus — "My patients ask me about peptides"

Route: the full book, weighted toward 5, 12, 19, 27, 28, 29, 37, 38, 39.

If you are a physician, nurse, pharmacist, PA, NP, dietitian, or trainer, the chapters that will change your practice fastest are Chapter 19 (what a gray-market vial actually risks), Chapter 29 (the approved peptide pharmacopeia you already prescribe without thinking of it as peptides), Chapter 37 (the master evidence table), and Chapter 39 (how to have this conversation without losing the patient). Chapter 12 covers the access and compounding questions your patients are already navigating without you.

What's in a chapter

Every chapter is a folder of seven files.

Read the second case study. In most textbooks it would be optional. In this one, the null results, the reversals, and the drugs that looked wonderful and then failed are where the actual lesson lives. The field's best teachers are its disappointments.

The exercises are the point

The exercises come in five recurring forms, drawn straight from what a reader actually needs to be able to do:

• "Evaluate this claim" — a paraphrased popular claim, set against the real evidence
• "Read this study" — interpret an abstract: design, population, endpoint, limitation
• "Compare the evidence" — two peptides, one indication, one standard applied to both
• "Identify the red flags" — an unreliable source, dissected
• "Explain this to a friend" — translate it into plain language, which is the only proof you actually understood it

Items marked with a dagger † have worked solutions in Appendix M. The others are deliberately left open; in a book about weighing evidence, an answer key that pretended every question had one right answer would be teaching the opposite of the lesson.

The progressive project: your Peptide Evidence Dossier

Running through all forty-four chapters is one project, and it is the thing most likely to still be useful to you in five years.

Choose 5 to 10 peptides you personally care about — the ones you have actually wondered about, not the ones you think you should pick. Semaglutide because your sister started it. BPC-157 because your training partner swears by it. Copper peptides because you own a \$90 bottle. Growth hormone because a clinic advertised it to you. Whatever brought you here.

Then, one chapter at a time, you fill in a twelve-field entry on each:

 1. IDENTITY        7. APPROVED USE
 2. ORIGIN          8. CLAIMED USE
 3. MECHANISM       9. RISKS
 4. PHARMACOLOGY   10. STATUS
 5. EVIDENCE       11. VERDICT
 6. RATING         12. WHAT WOULD CHANGE MY MIND

Each chapter ends with a 📋 Your Evidence Dossier checkpoint that teaches exactly one field or one skill and demonstrates it on a peptide from that chapter. By Chapter 40 you have a personal reference document — and, far more valuable, the habit that produced it.

Appendix C is the blank workbook. Print it, copy it into a notebook, or make a spreadsheet. The format matters much less than the discipline of field 12, which is where most people's thinking about health claims quietly falls apart.

The devices you will see repeatedly

Eight callouts, used throughout:

The evidence ladder appears first in Chapter 5 and recurs whenever a claim needs placing. ASCII diagrams carry all the visual content — pathways, axes, structures, timelines, trial designs — because there are no images in this book; every one is followed by a prose walkthrough.

About the ratings, one more time

You will see ✅, ⚠️, ❌, and 🔬 hundreds of times. Three things to hold onto:

1. A rating attaches to a claim, not a molecule. "Semaglutide: ✅" is meaningless. "Semaglutide for weight loss in adults with obesity: ✅" is a statement you can check.
2. ❌ means the confident version of a claim is not supported by human evidence. It does not mean "does not work." That distinction is the whole book, and Chapter 17 is where it is hardest and most important.
3. Every rating names what would change it. If you find one that doesn't, that is an error — please open an issue.

Reading time, honestly

Chapters average 8,000 to 12,000 words. Nobody reads one in a sitting, and nothing here requires that you do. The book is built to be picked up, put down, and — mostly — returned to when a specific question arrives.

One last thing before you start

If you are reading this because you are about to make a decision — about a drug, a clinic, an injury, a vial someone recommended — the most useful thing this book can do for you is not to provide an answer. It is to sharpen the question until it is one a clinician can actually help you with.

That is what Chapter 39 is for, and it is worth reading early if that is your situation.

Now, Chapter 1: what a peptide actually is.